I-Gefitinib CAS 184475-35-2 Ubunyulu> 99.5% (HPLC)
I-Shanghai Ruifu Chemical Co., Ltd. ngumenzi ohamba phambili weGefitinib (CAS: 184475-35-2) enomgangatho ophezulu.I-Ruifu Chemical inokubonelela ngenkonzo yehlabathi jikelele, ixabiso elikhuphisanayo, inkonzo egqwesileyo, encinci kunye nezixa ezininzi ezikhoyo.Thenga iGefitinib kunye nabaphakathi,Please contact: alvin@ruifuchem.com
| Igama leMchiza | Gefitinib |
| Izithethantonye | Isiseko sasimahla seGefitinib;Iressa;ZD1839;ZD-1839;N-(3-Chloro-4-Fluorophenyl)-7-Methoxy-6-(3-Morpholinopropoxy)quinazolin-4-Amine;N-(3-Chloro-4-Fluorophenyl)-7-Methoxy-6-[3-(4-Morpholinyl) propoxy]-4-Quinazolinamine |
| Ubume beStokhwe | Kwi-Stock, iMveliso yoRhwebo |
| Inombolo yeCAS | 184475-35-2 |
| Ifomula yeemolekyuli | I-C22H24ClFN4O3 |
| Ubunzima beMolekyuli | 446.91 g/mol |
| Indawo yokunyibilika | 194.0 ukuya 198.0℃ |
| Ukuxinana | 1.322±0.06 g/cm3 |
| Ukunyibilika kwamanzi | Ayinyibilikiyo emanzini |
| Ukunyibilika | Inyibilika kwi-DMSO |
| Ugcino Temp. | Ubushushu beGumbi |
| Ukuhambisa ngenqanawe | I-Ambient |
| I-COA kunye ne-MSDS | Iyafumaneka |
| Imvelaphi | Shanghai, China |
| Uphawu | Ruifu Chemical |
| Izinto | ImiGangatho yokuHlola | Iziphumo |
| Imbonakalo | Mhlophe ukuya kwi-Off-White Powder | Iyahambelana |
| Ilahleko ekomisweni | <0.50% | 0.13% |
| Intsalela kwi-Ignition | <0.20% | 0.06% |
| Ukungacoceki Okukodwa | <0.10% | 0.09% |
| Ukungcola ngokupheleleyo | <0.50% | 0.20% |
| Iintsimbi ezinzima (Pb) | ≤10ppm | <10ppm |
| Ubunyulu / Indlela yokuHlalutya | >99.5% (HPLC) | 99.80% |
| I-Infrared Spectrum | Ngokungqinelana noLwakhiwo | Iyahambelana |
| I-1H NMR Spectrum | Ngokungqinelana noLwakhiwo | Iyahambelana |
| Ukuqukumbela | Imveliso ivavanyiwe kwaye ihambelana neenkcukacha ezinikiweyo | |
Umqulu:Ibhotile eFluorinated, iAluminium foil bag, 25kg/Cardboard Drum, okanye ngokwemfuno yomthengi.
Imeko yoGcino:Gcina isikhongozeli sivaliwe kwaye usigcine kwindawo epholileyo, eyomileyo nengena umoya kakuhle kude nezinto ezingahambelaniyo.Khusela ukukhanya kunye nokufuma.
Ukuhambisa ngenqanawe:Zisa kwihlabathi liphela ngomoya, ngeFedEx / DHL Express.Ukubonelela ngokukhawuleza nangokuthembekileyo.
Ayisetyenziswa ebantwini.Ayisetyenziselwa ukuxilonga okanye kunyango.Ukusetyenziswa kophando lwe-in vitro kuphela.
Akukho nanye kwiimveliso eziya kubonelelwa kumazwe apho oku kunokungqubana namalungelo abenzi akhoyo.Nangona kunjalo uxanduva lokugqibela likuMthengi.
Ukuthenga njani?Nceda uqhagamshelaneDr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com
Amava Eminyaka Eli-15?Sineminyaka engaphezu kwe-15 yamava ekwenziweni nasekuthumeleni kumazwe angaphandle uluhlu olubanzi oluphezulu lwamayeza aphakathi okanye amachiza alungileyo.
Iimarike eziphambili?Thengisa kwimarike yasekhaya, eMntla Melika, eYurophu, eIndiya, eKorea, eJapan, eOstreliya, njl.
Iingenelo?Umgangatho ophezulu, ixabiso elifikelelekayo, iinkonzo zengcali kunye nenkxaso yobugcisa, ukuhanjiswa ngokukhawuleza.
UmgangathoIsiqinisekiso?Inkqubo yokulawula umgangatho ongqongqo.Izixhobo zobuchwephesha zokuhlalutya ziquka i-NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, KF, ROI, LOD, MP, Clarity, Solubility, Microbial limit test, njl.
Iisampulu?Uninzi lweemveliso zibonelela ngeesampulu zasimahla zokuvavanya umgangatho, iindleko zokuthumela kufuneka zihlawulwe ngabathengi.
Factory Audit?Uphicotho-zincwadi lwasefektri wamkelekile.Nceda wenze idinga kwangaphambili.
MOQ?Akukho MOQ.Umyalelo omncinci wamkelekile.
Ixesha lokuzisa? Ukuba ngaphakathi kwesitokhwe, ukuhanjiswa kweentsuku ezintathu kuqinisekisiwe.
Ezothutho?Nge-Express (FedEx, DHL), ngoMoya, ngoLwandle.
Amaxwebhu?Emva kwenkonzo yokuthengisa: I-COA, i-MOA, i-ROS, i-MSDS, njl.
Udibaniso lweSiko?Inokubonelela ngeenkonzo zesiko lokudibanisa ukuze zilungele iimfuno zakho zophando.
Immimiselo yokuhlawula?I-invoyisi yeProforma iya kuthunyelwa kuqala emva kokuqinisekiswa kwe-odolo, efakwe kwiinkcukacha zethu zebhanki.Intlawulo nge-T / T (i-Telex Transfer), i-PayPal, i-Western Union, njl.
| Inkcazelo yoKhuseleko | 24/25 - Gwema ukudibana nolusu kunye namehlo. |
| Ikhowudi ye-HS | 2934999099 |
I-Gefitinib (i-CAS: i-184475-35-2) iyeza elithile elichasayo elijoliswe kwi-tumor elenziwe ngu-AstraZeneca, e-UK.Lichiza lokuqala elijoliswe kwimolekyuli kunyango lomhlaza wemiphunga weseli ongemncinci.Isebenza ngokuthintela ngokukhethekileyo indlela yokudluliselwa kwesignali ye-epidermal growth factor receptor tyrosine kinase (EGFR-TK).I-Epidermal growth factor (EGF) yi-polypeptide ene-molecular mass ye-6.45 × 103, enokudibanisa ne-epidermal growth factor receptor (EGFR) kwi-membrane yeseli ekujoliswe kuyo ukuvelisa iziphumo ze-biological.I-EGFR yi-tyrosine kinase (TK) uhlobo lwe-receptor.Xa ibophelela kwi-EGF, inokukhuthaza ukusebenza kwe-TK kumzimba wommkeli, okubangelwa i-autophosphorylation ye-receptor tyrosine i-residues, ukubonelela ngezibonakaliso eziqhubekayo zokwahlula kwiiseli, ezibangela ukwanda kweeseli kunye nokuhlukana.I-EGFR ininzi kwizicubu zomntu kwaye ibonakaliswe kakhulu kwiithumba ezinobungozi.Ngokuthintela i-EGFR indlela yokubonisa i-cell surface, i-gefitinib ithintela ukukhula kwe-tumor, i-metastasis kunye ne-angiogenesis, kwaye inokubangela i-apoptosis yeeseli ze-tumor.Ngo-Agasti ka-2002, i-gefitinib yaqala ukuthengiswa e-Japan njengonyango lodidi lokuqala lomhlaza wemiphunga weseli ongenguwo omncinci phantsi kwegama lokurhweba elithi Iressa.NgoMeyi ka-2003, i-US Food and Drug Administration yavuma i-gefitinib njengonyango lwe-monotherapy yodidi lwesithathu kwizigulana ezinomhlaza wemiphunga weseli engeyiyo encinci nengazange isebenze ngamachiza e-anticancer asekwe kwiplatinam kunye ne-docetaxel chemotherapy.Okwangoku, ivunyiwe yi-Australia, iJapan, iArgentina, iSingapore kunye noMzantsi Korea kunyango lomhlaza wemiphunga weseli ongewona mncinci.Ngomhla wama-28 kaFebruwari 2005, i-China Food and Drug Administration yavuma i-gefitinib kunyango lomhlaza wemiphunga weseli ophucukileyo okanye one-metastatic engeyiyo encinci (NSCLC) eyayifumene ichemotherapy ngaphambili.Ayikavunywa okwangoku ukuba isetyenziswe njengonyango lodidi lokuqala lwe-NSCLC ephucukileyo.Ngomhla woku-1 kuJulayi, ka-2009, i-Arhente yaMayeza yaseYurophu yavuma ngokusesikweni i-gefitinib yonyango lodidi lokuqala, lodidi lwesibini kunye nodidi lwesithathu lomhlaza wemiphunga weseli ophucukileyo okanye onesimetastatic ongengowomncinci oneenguqu zemfuza ze-EGFR kubantu abadala.
